Response Biomedical Corp. (RBM.TO)
-Toronto 3.50 
0.05(1.41%) May 17, 3:36PM EDT
| Prev Close: | 3.55 |
|---|
| Open: | 3.50 |
|---|
| Bid: | 3.31 |
|---|
| Ask: | 3.50 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 3.40 - 3.50 |
|---|
| 52wk Range: | 0.95 - 5.75 |
|---|
| Volume: | 2,900 |
|---|
| Avg Vol (3m): | 4,117 |
|---|
| Market Cap: | 22.74M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in CAD.
Headlines
- Response Biomedical Corp. Announces 2013 First Quarter Financial ResultsMarketwired(Mon, May 13)
- Q1 2013 Response Biomedical Corp Earnings Release - After Market CloseCCBN(Mon, May 13)
- Response Biomedical Corp. Schedules First Quarter 2013 Earnings Release and Conference Call and Announces Participation in Upcoming Investor ConferenceMarketwired(Tue, May 7)
- Response Biomedical Corp. Announces Fourth Quarter and Fiscal 2012 Financial ResultsMarketwired(Mon, Mar 11)
- Q4 2012 Response Biomedical Corp Earnings Release - After Market CloseCCBN(Mon, Mar 11)
- Response Biomedical Corp. Schedules Fourth Quarter and Fiscal Year 2012 Earnings Release and Announces Conference CallMarketwired(Wed, Mar 6)
- Response Biomedical Corp. Announces the Hire of Mr. Darby L. Darilek as Director of U.S. Sales to Expand Its Presence and Commitment to the U.S. MarketMarketwired(Tue, Feb 26)
- Response Biomedical Corp. Announces Execution of New Distribution Agreement with Fisher HealthCare for U.S. Distribution of its Response Infectious Disease ProductsMarketwired(Thu, Jan 24)
- Response Biomedical Corp. Announces Expansion of U.S. Distribution for RAMP(R) Cardiovascular ProductsMarketwired(Thu, Jan 3)
- Response Biomedical Corp. to Present at Upcoming Investor ConferenceMarketwired(Wed, Jan 2)
- Response Biomedical Corp. Announces Third Quarter 2012 Financial ResultsMarketwired(Wed, Nov 14)
- Response Biomedical Corporation Schedules Third Quarter 2012 Earnings Release and Announces Conference CallMarketwired(Wed, Nov 7)
- Response Biomedical Corp. Announces the CE Mark of D-dimer Assay for the EU MarketMarketwired(Wed, Nov 7)
- Response Biomedical Corporation Announces Acquisition of Worldwide Rights of Infectious Disease Testing Due to Termination of 3M AgreementsMarketwired(Tue, Oct 2)
- Response Biomedical Corp. Announces Share ConsolidationMarketwired(Mon, Sep 24)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 1.96 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(0-00-31)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Response Biomedical Corp. engages in the research, development, commercialization, and distribution of diagnostic technologies for the medical point of care (POC) and on-site environmental testing markets.
View More